Intellipharmaceutics International Inc. Stock Company Profile

Description

Intellipharmaceutics International Inc., a pharmaceutical company, engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. The company develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders. The company also develops Rexista Oxycodone XR, an abuse and alcohol-deterrent controlled-release oral formulation of oxycodone hydrochloride for the relief of pain; Regabatin XR, a pregabalin extended-release capsule use for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration that contains venlafaxine hydrochloride; Protonix, a delayed-release capsule for oral administration that contains pantoprazole sodium; and Glucophage, an oral antihyperglycemia drug used in the management of type 2 diabetes. In addition, its products include Seroquel XR, an oral psychotropic agent use for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug used in the treatment of epilepsy; Keppra XR, an antiepileptic drug indicated for the treatment of partial onset seizures in patients with epilepsy; and Pristiq, an inhibitor use for the treatment of major depressive disorder. Intellipharmaceutics International Inc. has a license and commercialization agreement with Par Pharmaceutical, Inc. The company was founded in 1998 and is based in Toronto, Canada.